Alzheimer, Parkinson Disease Share Protective Association at HLA Locus
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, Sept. 8, 2023 -- Alzheimer disease (AD) and Parkinson disease (PD) share the same protective association at the human leukocyte antigen (HLA) locus, according to a study published online Aug. 29 in the Proceedings of the National Academy of Sciences.
Yann Le Guen, Ph.D., from Stanford University in California, and colleagues examined HLA associations in more than 176,000 individuals with PD and AD compared to controls across multiancestry groups.
The researchers found that the diseases shared the same protective association at the HLA locus. The association was best accounted for by the hierarchical protective effects of HLA-DRB1*04 subtypes, which were strongest with HLA-DRB1*04:04 and HLA-DRB1*04:07 and intermediate with HLA-DRB1*04:01 and HLA-DRB1*04:03. In postmortem brains, the same signal was associated with reduced neurofibrillary tangles; the signal was also associated with reduced tau levels in cerebrospinal fluid and with increased Aβ42 to a lesser extent. When acetylated at a lysine (K311), protective HLA-DRB1*04 subtypes strongly bound the aggregation-prone tau PHF6 sequence.
"Our results also open the possibility that targeting tau epitopes containing acetylated-K311 through chimeric antigen receptor T cells or antibodies could have therapeutic values," the authors write.
Two authors filed a patent application on this discovery.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.